LEMAITRE VASCULAR INC LMAT
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
7/9
Piotroski F — financial health
8.18
Altman Z″ — distress risk · safe
31.4%
Dividend payout · safe
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $249.6M | $57.7M | $178.5M | — | $393.5M |
| 2024 | $219.9M | $44.0M | $150.9M | — | $337.3M |
| 2023 | $193.5M | $30.1M | $127.0M | — | $297.9M |
| 2022 | $161.7M | $20.6M | $104.9M | — | $268.2M |
| 2021 | $154.4M | $26.9M | $101.4M | — | $254.2M |
| 2020 | $129.4M | $21.2M | $84.6M | — | $172.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| LeMaitre George W | Chairman and CEO | 2026-06-04 | Gift | 11,974 | — |
| LeMaitre George W | Chairman and CEO | 2026-06-04 | Grant | 11,974 | — |
| LeMaitre George W | Chairman and CEO | 2026-05-08 | Sell | 27,881 | $108.69 |
| LeMaitre George W | Chairman and CEO | 2026-05-07 | Sell | 18,600 | $107.64 |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.18 (safe)
- Working capital / assets 0.702
- Retained earnings / assets 0.3
- EBIT / assets 0.11
- Equity / liabilities 1.771
Source: SEC EDGAR filings · CIK 0001158895 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.